G. Alton

发表

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

J. Christensen, B. Mroczkowski, L. Funk, 2011, Journal of medicinal chemistry.

Characterization of the CHK1 allosteric inhibitor binding site.

G. Alton, J. Register, J. Ermolieff, 2009, Biochemistry.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

Shinji Yamazaki, J. Christensen, B. Mroczkowski, 2007, Molecular Cancer Therapeutics.

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

Shinji Yamazaki, Gordon Alton, Pei-Pei Kung, 2007, Cancer research.

Antisense Inhibition of S6 Kinase 1 Produces Improved Glucose Tolerance and Is Well Tolerated for 4 Weeks of Treatment in Rats

G. Alton, J. Heyen, B. Hirakawa, 2010, Pharmacology.

Identification of a Structural Determinant

G. Alton, P. Webb, E. Levin, 2002 .

Novel small molecule inhibitors of the OLIG2 transcription factor: promising new therapeutics for glioblastoma.

S. Kesari, G. Alton, 2016, Future oncology.

Use of human-milk fucosyltransferase in the chemoenzymic synthesis of analogues of the sialyl Lewis(a) and sialyl Lewis(x) tetrasaccharides modified at the C-2 position of the reducing unit.

G. Alton, M. Kashem, A. Venot, 1993, Carbohydrate research.

Molecular cloning, gene organization, and expression of mouse Mpi encoding phosphomannose isomerase.

H. Freeze, G. Alton, J. A. Davis, 2002, Glycobiology.

Combined chemical-enzymic synthesis of an internally monofucosylated hexasaccharide corresponding to the CD-65/VIM-2 epitope: use of a terminal alpha 2-6-linked N-acetylneuraminic acid as a temporary blocking group.

G. Alton, M. Kashem, A. Venot, 1992, Carbohydrate research.

Combined chemical-enzymic synthesis of deoxygenated oligosaccharide analogs: transfer of deoxygenated D-GlcpNAc residues from their UDP-GlcpNAc derivatives using N-acetylglucosaminyltransferase I.

G. Alton, O. Hindsgaul, G. Srivastava, 1990, Carbohydrate research.

Assay optimization and kinetic profile of the human and the rabbit isoforms of 11beta-HSD1.

P. Rejto, G. Alton, J. Ermolieff, 2007, Biochemical and biophysical research communications.

Identification of novel pyrrolopyrazoles as protein kinase C β II inhibitors.

D. Bouzida, Iriny Botrous, G. Alton, 2011, Bioorganic & medicinal chemistry letters.

Potent and selective thiophene urea-templated inhibitors of S6K.

G. Alton, R. Stanton, Natasha M. Kablaoui, 2011, Bioorganic & medicinal chemistry letters.

Isolation and characterization of behavioural mutants and genes of Agrobacterium tume

G. Alton, G. Loake, C. Garrett, 2008 .

Catalytic mechanism of the quinoenzyme amine oxidase from Escherichia coli: exploring the reductive half-reaction.

M. R. Parsons, M. McPherson, C. Wilmot, 1997, Biochemistry.

Targeting the unactivated conformations of protein kinases for small molecule drug discovery

E. Lunney, G. Alton, 2008, Expert opinion on drug discovery.

Stereochemistry and cofactor identity status of semicarbazide-sensitive amine oxidases.

G. Alton, M. Palcic, C. Scaman, 1995, Progress in brain research.

An enzyme-linked immunosorbent assay for N-acetylglucosaminyltransferase-V.

G. Alton, M. Palcic, S. Crawley, 1990, Analytical biochemistry.

Use of N-acetylglucosaminyltransferases I and II in the synthesis of a dideoxypentasaccharide.

G. Alton, O. Hindsgaul, K. Kaur, 1994, Bioorganic & medicinal chemistry.

The use of a synthetic dideoxygenated pentasaccharide as a specific acceptor for N-acetylglucosaminyltransferase-III.

G. Alton, Y. Kanie, O. Hindsgaual, 1993, Carbohydrate research.

Use of N-acetylglucosaminyltransferases I and II in the preparative synthesis of oligosaccharides.

G. Alton, O. Hindsgaul, K. Kaur, 1991, Carbohydrate research.

An enzyme-linked immunosorbent assay for the measurement of Lewis blood-group α-(1→4)-fucosyltransferase activity

G. Alton, M. Palcic, O. Hindsgaul, 1990 .

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

J. Christensen, M. McTigue, K. Ryan, 2009, Biochemistry.

Therapeutic modulation of inflammatory gene transcription by kinase inhibitors

G. Alton, J. Westwick, K. Schwamborn, 2002, Expert opinion on biological therapy.

VPR-254: an inhibitor of ROR-gamma T with potential utility for the treatment of inflammatory bowel disease

G. Alton, L. Fitzpatrick, Jeffrey S. Small, 2019, Inflammopharmacology.

Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).

S. Kazmirski, M. Hickey, G. Alton, 2011, Journal of medicinal chemistry.

Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery

Qiyue Hu, M. Catherine Johnson, Laura Lingardo, 2011, J. Comput. Aided Mol. Des..

A Novel ROR-Gamma T Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice

G. Alton, L. Fitzpatrick, J. Zapf, 2017 .

90 Efficacy of a Novel Small Molecule RORgt Inverse Agonist in Mouse DSS and TNBS Models of Inflammatory Bowel Disease

G. Alton, L. Fitzpatrick, Jeffrey S. Small, 2015 .

Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1).

Justin Chapman, Laura Lingardo, Dario R Alessi, 2010, The Biochemical journal.

Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function.

G. Alton, J. Monahan, T. Kern, 2010, Investigative ophthalmology & visual science.

DDIS-19. CT-179: AN INHIBITOR OF THE OLIG2 TRANSCRIPTION FACTOR WITH POTENT ANTI-TUMOUR ACTIVITY IN BRAIN CANCER

S. Kesari, G. Alton, Shengnan Chen, 2018, Neuro-Oncology.

Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays.

S. Gridley, G. Alton, M. Gehring, 2011, Analytical biochemistry.

VPR-254: an inhibitor of ROR-gamma T with potential utility for the treatment of inflammatory bowel disease

G. Alton, L. Fitzpatrick, Jeffrey S. Small, 2019, Inflammopharmacology.

Isolation and characterization of behavioural mutants and genes of Agrobacterium tumefaciens

G. Alton, G. Loake, C. Shaw, 1991 .

Identification of the quinone cofactor in mammalian semicarbazide-sensitive amine oxidase.

G. Alton, M. Palcic, C. Scaman, 1998, Biochemistry.

Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.

H. Freeze, G. Alton, K. von Figura, 1998, The Journal of clinical investigation.

Functional proteomics analysis of GTPase signaling networks.

G. Alton, J. Westwick, A. Cox, 2001, Methods in enzymology.

Identification of a Structural Determinant Necessary for the Localization and Function of Estrogen Receptor α at the Plasma Membrane

G. Alton, P. Webb, E. Levin, 2003, Molecular and Cellular Biology.

Stereochemistry of benzylamine oxidation by copper amine oxidases.

G. Alton, M. Palcic, R. Beever, 1995, Archives of biochemistry and biophysics.